title: Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease.
abstract: OBJECTIVE
  To study the efficacy and incidence of treatment-related side effects of mycophenolate mofetil (MMF) therapy in patients with noninfectious inflammatory eye diseases.
  
  
  METHODS
  Retrospective cohort study of 27 Chilean patients treated for noninfectious inflammatory eye diseases using MMF therapy over a 10-year period. Main outcome measures were: ability to control ocular inflammation and to taper prednisone to ≤10 mg daily (treatment success); incidence of treatment-related side effects.
  
  
  RESULTS
  The proportion of patients with sustained control of inflammation was 81.48% at 6 months. Additionally 55.56% and 22.22% of patients succeeded in tapering their prednisone to 5-10 mg/day and <5 mg/day, at 6 months. Two patients developed a neoplasia during MMF therapy; however, this cohort is too small to interpret the significance of this relation to MMF treatment.
  
  
  CONCLUSIONS
  MMF seems to be an effective corticosteroid-sparing agent with an acceptable safety profile.
authors.affiliation: 1 Department of Medicine, Clinical Hospital University of Chile , Santiago, Chile .
authors.forename: Miguel
authors.initials: M
authors.lastname: Cuchacovich
authors.affiliation: 2 Ophthalmology Department, Clinical Hospital, Catholic University of Chile , Santiago, Chile .
authors.forename: Federica
authors.initials: F
authors.lastname: Solanes
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Claudio
authors.initials: C
authors.lastname: Perez
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Juan Ignacio
authors.initials: JI
authors.lastname: Verdaguer
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Juan
authors.initials: J
authors.lastname: Verdaguer
authors.affiliation: 2 Ophthalmology Department, Clinical Hospital, Catholic University of Chile , Santiago, Chile .
authors.forename: Enzo
authors.initials: E
authors.lastname: Castiglione
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Cristian
authors.initials: C
authors.lastname: Carpentier
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Leonidas
authors.initials: L
authors.lastname: Traipe
authors.affiliation: 3 Los Andes Ophthalmologic Foundation, Los Andes University , Santiago, Chile .
authors.forename: Francisco
authors.initials: F
authors.lastname: Villarroel
mesh_terms: D000328:Adult; D002677:Chile; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000175:diagnosis / Q000188:drug therapy*; D007634:Keratitis / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D015423:Scleritis / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid